Triple the dose, with a monthly increase of only $50: Novo Nordisk A/S Sponsored ADR Class B (NVO.US) boosts the dose of Wegovy to compete with Eli Lilly and Company's Zepbound (LLY.US).

Novo Nordisk A/S Sponsored ADR Class B announced that it will price its new high-dose weight loss drug, Wegovy, at $399 per month for self-pay patients, a price lower than the majority of specifications of its competitor Eli Lilly's Zepbound. Novo Nordisk A/S Sponsored ADR Class B stated that the high-dose version of Wegovy will officially launch this Tuesday. The pricing is about 40% lower than the price for the first three high-dose specifications of Zepbound for self-pay patients. This more potent drug is an important part of Novo Nordisk A/S Sponsored ADR Class B's strategy to catch up with Eli Lilly. A previous clinical trial showed that Zepbound had better weight loss effects than the standard dose Wegovy. With its more significant weight loss effects, Eli Lilly's drug has become the best-selling injectable weight loss drug in the US. Novo Nordisk A/S Sponsored ADR Class B hopes that the new formulation of Wegovy will drive performance. The oral version of Wegovy launched in January this year had the best market performance in the history of weight loss drugs. Last week, the Danish pharmaceutical company also introduced a subscription service, where patients can enjoy lower monthly fees for Wegovy if they sign up for several months of treatment. The new injectable, named Wegovy HD, has a drug dose of 7.2 milligrams, three times higher than the previously highest dose available on the market, and the monthly self-pay price is only $50 higher. Self-pay patients can purchase it through Novo Nordisk A/S Sponsored ADR Class B's direct-to-consumer platform NovoCare, conventional pharmacy channels, and designated telemedicine partners. A spokesperson for Novo Nordisk A/S Sponsored ADR Class B stated that depending on the telemedicine institution, the new high-dose product will be included in some subscription packages at standard subscription prices.